| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
7-Octen-1-ol does not have a defined pharmacological target of its own, as it is a synthetic intermediate and chemical reagent. As an unsaturated alcohol, it serves as a building block for the synthesis of various compounds. The terminal alkene and primary alcohol provide handles for further derivatization in organic synthesis and medicinal chemistry.
|
|---|---|
| ln Vitro |
In vitro, 7-Octen-1-ol is primarily used as a chemical reagent and synthetic intermediate. It is utilized as a biomaterial or organic/chemical reagent for biomedical research. As an unsaturated alcohol, it is a common building block for the construction of more complex molecules through reactions such as epoxidation, hydroboration, and oxidation.
|
| ln Vivo |
In vivo activity data for 7-Octen-1-ol itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound's in vivo relevance is indirect, through the biological activities of the final pharmaceutical compounds derived from it.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, 7-Octen-1-ol is not typically evaluated as a test compound itself. Instead, it serves as a reagent for the synthesis of test compounds. The compound's properties include a molecular weight of 128.21 g/mol, a boiling point of 66°C at 7 mmHg, a flash point of 74°C, and appearance as a colorless to almost colorless clear liquid.
|
| Cell Assay |
For in vitro cell-based experiments, 7-Octen-1-ol is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations.
|
| Animal Protocol |
In vivo animal studies using 7-Octen-1-ol are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with appropriate pharmacokinetic and pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-Octen-1-ol as a standalone compound are not characterized in the literature. The compound has a molecular weight of 128.21 g/mol, which is within the favorable range for oral bioavailability. The boiling point is 66°C at 7 mmHg and the flash point is 74°C. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
7-Octen-1-ol is a research chemical and should be handled with appropriate laboratory safety precautions. As an alcohol, it may pose risks of skin and eye irritation. The compound has a flash point of 74°C and should be stored away from heat and open flames. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
There have been reports of 7-octen-1-ol being found in Aristolochia debilis, and relevant data are available for reference.
7-Octen-1-ol (CAS 13175-44-5) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a biomaterial or organic/chemical reagent for biomedical research. As an unsaturated alcohol, it serves as a building block for the synthesis of more complex molecules. No clinical trials or approved indications exist for this compound. It is intended for laboratory research use only. |
| Molecular Formula |
C8H16O
|
|---|---|
| Molecular Weight |
128.21
|
| Exact Mass |
128.12
|
| CAS # |
13175-44-5
|
| PubChem CID |
83203
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.8±0.1 g/cm3
|
| Boiling Point |
188.1±19.0 °C at 760 mmHg
|
| Flash Point |
74.3±13.2 °C
|
| Vapour Pressure |
0.2±0.8 mmHg at 25°C
|
| Index of Refraction |
1.440
|
| LogP |
2.49
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
9
|
| Complexity |
59.6
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CCCCCCCO
|
| InChi Key |
WXPWPYISTQCNDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H16O/c1-2-3-4-5-6-7-8-9/h2,9H,1,3-8H2
|
| Chemical Name |
oct-7-en-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (779.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.7997 mL | 38.9985 mL | 77.9970 mL | |
| 5 mM | 1.5599 mL | 7.7997 mL | 15.5994 mL | |
| 10 mM | 0.7800 mL | 3.8999 mL | 7.7997 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
